Articles On Imugene (ASX:IMU)

Health and medical industry of Australia focuses on the world’s leading technology, advanced research, development and innovation. Over the years, the industry has registered strong growth in terms of both size and reputation. Let us discus...

HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours in gastric, breast, ovarian, lung and pancreatic cancers.

An Australian-headquartered clinical stage immuno-oncology company, Imugene Limited (ASX: IMU) has a robust pipeline of B cell vaccines aimed at treating a variety of cancers. The company’s pipeline includes multiple product candidates that...

The movement of global stock markets is very sensitive to the news which is associated with the trade battle between the US & China, and other macro-economic variables. Not so long ago, it can be said that the global market players were...

Imugene Limited (ASX: IMU) is a clinical-stage immuno-oncology company headquartered in Australia that is engaged in developing a range of immunotherapies used to treat and eradicate tumors. The company’s operations are spread across Americ...

Imugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.

Imugene (ASX:IMU) is a clinical stage life sciences company on the cutting edge of this very field and is developing vaccines to boost and direct the immune system to target and attack cancer cells.